Benzinga

Benzinga

Benzinga

mercoledì, settembre 09

Elevance Health Inc

ELVNYSE
Trade with Public
Trade with Public
$401.94
-5.56-1.36%
In chiusura: Sep 4, 5:00 PM EST
$401.94
-5.56-1.36%
Pre-mercato: 6:48 AM EST
Dividendo: La data di stacco del dividendo è domani
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy
6Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$438Upside to Avg. PT+8.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 17, 2026Leerink PartnersWhit MayoPT RaiseMarket Perform$364→$395
Jul 16, 2026RBC CapitalBen HendrixPT CutSector Perform$439→$424
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved